Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Dermata Therapeutics Inc. Warrant (DRMAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DRMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4154323 |
Shares Outstanding - | Shares Floating 4154323 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Dermata Therapeutics Inc. Warrant
Company Overview
History and Background
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing innovative, differentiated, and proprietary solutions for dermatological conditions. The warrant analysis will focus on the investment instrument related to the company. The company was founded in 2014 and went public in 2021.
Core Business Areas
- Medical Dermatology: Focuses on developing and commercializing innovative treatments for dermatological conditions like acne, rosacea, and psoriasis.
Leadership and Structure
The leadership team includes executives with experience in dermatology, pharmaceutical development, and commercialization. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- DRM01: DRM01 (under research) is an innovative treatment option for common skin conditions and diseases
- DRM02: DRM02 is a sebum-reducing and anti-inflammatory agent being developed for the treatment of acne and rosacea. As the product is in clinical trials, it currently has no market share or revenue. Competitors include companies with approved acne and rosacea treatments like Galderma, Almirall, and others developing similar products.
- DRM04: DRM04 is a small molecule being developed for the treatment of hyperhidrosis (excessive sweating). As the product is in clinical trials, it currently has no market share or revenue. Competitors include companies with approved hyperhidrosis treatments like Brickell Biotech and others developing similar products.
Market Dynamics
Industry Overview
The dermatology market is large and growing, driven by an aging population, increasing awareness of skin health, and the availability of new and innovative treatments. The industry is competitive, with numerous companies developing and marketing dermatological products.
Positioning
Dermata Therapeutics aims to position itself as a leader in the medical dermatology space by developing innovative and differentiated products that address unmet needs in the treatment of common skin conditions. Their strategy focuses on proprietary solutions for dermatology conditions.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth billions of dollars. Dermata is positioned to capture a share of this market with successful development and commercialization of their product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced management team
- Pipeline of promising product candidates
- Focus on unmet needs in dermatology
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources
- High risk of failure in drug development
Opportunities
- Potential to develop and commercialize innovative dermatology products
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new dermatological indications
- Growing dermatology market
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unsuccessful clinical trial outcomes
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VRX
- AGN
- LLY
Competitive Landscape
Dermata Therapeutics faces competition from established pharmaceutical companies with approved dermatology products and other companies developing similar products. The company's success depends on the differentiation and efficacy of its product candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of product candidates through preclinical and clinical development.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of its product candidates.
Recent Initiatives: Recent initiatives include advancing the clinical development of DRM02 and DRM04 and exploring strategic partnerships.
Summary
Dermata Therapeutics is a clinical-stage company with promising product candidates. The company is still young and relies on the success of clinical trials and funding. The company needs to be careful about competition from established companies. Successful development of DRM02 and DRM04 is key for future growth. Their proprietary technology and management experience are strengths to leverage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in clinical-stage biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc. Warrant
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.